Abstract P6-10-09: Multispectral immunofluorescence (mIF) to detect dynamic changes in PD-L1 expression, immune cell (IC) infiltration, and tumor-IC interactions in primary breast cancer (BC) immuno-oncology (I-O) clinical trials

Katherine Sanchez; Isaac Kim; ShuChing Chang; Maritza Martel; Yaping Wu; Brady Bernard; Joanna Pucilowska; Zhaoyu Sun; William Redmond; Dottie Waddell; Walter Urba; David B Page

doi:10.1158/1538-7445.SABCS19-P6-10-09

Abstract P6-10-09: Multispectral immunofluorescence (mIF) to detect dynamic changes in PD-L1 expression, immune cell (IC) infiltration, and tumor-IC interactions in primary breast cancer (BC) immuno-oncology (I-O) clinical trials

Katherine Sanchez, Isaac Kim, ShuChing Chang, Maritza Martel, Yaping Wu, Brady Bernard, Joanna Pucilowska, Zhaoyu Sun, William Redmond, Dottie Waddell, Walter Urba, David B Page

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cancer Research
Volume	80
DOIs	https://doi.org/10.1158/1538-7445.SABCS19-P6-10-09
State	Published - Feb 15 2020

Disciplines

Oncology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1158/1538-7445.SABCS19-P6-10-09License: Unspecified

Cite this

Sanchez, K., Kim, I., Chang, S., Martel, M., Wu, Y., Bernard, B., Pucilowska, J., Sun, Z., Redmond, W., Waddell, D., Urba, W., & Page, D. B. (2020). Abstract P6-10-09: Multispectral immunofluorescence (mIF) to detect dynamic changes in PD-L1 expression, immune cell (IC) infiltration, and tumor-IC interactions in primary breast cancer (BC) immuno-oncology (I-O) clinical trials. Cancer Research, 80. https://doi.org/10.1158/1538-7445.SABCS19-P6-10-09

@article{69d92c027b334a05946cf059fb2e3bcc,

title = "Abstract P6-10-09: Multispectral immunofluorescence (mIF) to detect dynamic changes in PD-L1 expression, immune cell (IC) infiltration, and tumor-IC interactions in primary breast cancer (BC) immuno-oncology (I-O) clinical trials",

author = "Katherine Sanchez and Isaac Kim and ShuChing Chang and Maritza Martel and Yaping Wu and Brady Bernard and Joanna Pucilowska and Zhaoyu Sun and William Redmond and Dottie Waddell and Walter Urba and Page, {David B}",

note = "Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas Introduction: Anti-PD-1/L1 (atezolizumab) is effective in first-line, PD-L1-positive triple negative breast cancer, however it is becoming increasingly apparent that the majority of breast cancers will require novel I-O combination strategies.",

year = "2020",

month = feb,

day = "15",

doi = "10.1158/1538-7445.SABCS19-P6-10-09",

language = "American English",

volume = "80",

journal = "Cancer Research",

}

Sanchez, K, Kim, I, Chang, S, Martel, M, Wu, Y, Bernard, B, Pucilowska, J, Sun, Z, Redmond, W, Waddell, D, Urba, W & Page, DB 2020, 'Abstract P6-10-09: Multispectral immunofluorescence (mIF) to detect dynamic changes in PD-L1 expression, immune cell (IC) infiltration, and tumor-IC interactions in primary breast cancer (BC) immuno-oncology (I-O) clinical trials', Cancer Research, vol. 80. https://doi.org/10.1158/1538-7445.SABCS19-P6-10-09

Abstract P6-10-09: Multispectral immunofluorescence (mIF) to detect dynamic changes in PD-L1 expression, immune cell (IC) infiltration, and tumor-IC interactions in primary breast cancer (BC) immuno-oncology (I-O) clinical trials. / Sanchez, Katherine; Kim, Isaac; Chang, ShuChing et al.
In: Cancer Research, Vol. 80, 15.02.2020.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Abstract P6-10-09: Multispectral immunofluorescence (mIF) to detect dynamic changes in PD-L1 expression, immune cell (IC) infiltration, and tumor-IC interactions in primary breast cancer (BC) immuno-oncology (I-O) clinical trials

AU - Sanchez, Katherine

AU - Kim, Isaac

AU - Chang, ShuChing

AU - Martel, Maritza

AU - Wu, Yaping

AU - Bernard, Brady

AU - Pucilowska, Joanna

AU - Sun, Zhaoyu

AU - Redmond, William

AU - Waddell, Dottie

AU - Urba, Walter

AU - Page, David B

N1 - Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas Introduction: Anti-PD-1/L1 (atezolizumab) is effective in first-line, PD-L1-positive triple negative breast cancer, however it is becoming increasingly apparent that the majority of breast cancers will require novel I-O combination strategies.

PY - 2020/2/15

Y1 - 2020/2/15

UR - https://cancerres.aacrjournals.org/content/80/4_Supplement/P6-10-09.short

U2 - 10.1158/1538-7445.SABCS19-P6-10-09

DO - 10.1158/1538-7445.SABCS19-P6-10-09

M3 - Article

VL - 80

JO - Cancer Research

JF - Cancer Research

ER -

Abstract P6-10-09: Multispectral immunofluorescence (mIF) to detect dynamic changes in PD-L1 expression, immune cell (IC) infiltration, and tumor-IC interactions in primary breast cancer (BC) immuno-oncology (I-O) clinical trials

Disciplines

Access to Document

Other files and links

Cite this